U.S. markets open in 9 hours 14 minutes
  • S&P Futures

    4,071.75
    +13.00 (+0.32%)
     
  • Dow Futures

    33,623.00
    +115.00 (+0.34%)
     
  • Nasdaq Futures

    13,051.50
    +53.00 (+0.41%)
     
  • Russell 2000 Futures

    2,141.60
    +10.10 (+0.47%)
     
  • Crude Oil

    65.47
    -0.61 (-0.92%)
     
  • Gold

    1,816.50
    -6.30 (-0.35%)
     
  • Silver

    27.10
    -0.14 (-0.51%)
     
  • EUR/USD

    1.2077
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.6950
    +0.0710 (+4.37%)
     
  • Vix

    27.59
    +5.75 (+26.33%)
     
  • GBP/USD

    1.4060
    +0.0002 (+0.02%)
     
  • USD/JPY

    109.7420
    +0.0820 (+0.07%)
     
  • BTC-USD

    50,858.60
    -7,055.39 (-12.18%)
     
  • CMC Crypto 200

    1,386.95
    -176.88 (-11.31%)
     
  • FTSE 100

    7,004.63
    +56.64 (+0.82%)
     
  • Nikkei 225

    27,682.42
    -465.09 (-1.65%)
     

Inspire Medical Systems, Inc. to Report First Quarter 2021 Financial Results on May 4, 2021

  • Oops!
    Something went wrong.
    Please try again later.
Inspire Medical Systems, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

MINNEAPOLIS, April 06, 2021 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the first quarter 2021 after the close of trading on Tuesday, May 4. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

Tuesday, May 4th @ 5:00 p.m. Eastern Time:

Domestic:

877-407-0792

International:

201-689-8263

Conference ID:

13717525

Webcast:

http://public.viavid.com/index.php?id=143909

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact:
Bob Yedid
LifeSci Advisors
inspire@lifesciadvisors.com
646-597-6989